Endacea, Inc. - About Us

In addition to sepsis, asthma, and renal impairment, including renal impairment associated with acute or chronic heart failure or nephrotoxins, Endacea believes that other indications for L-97-1 or a follow-on molecule from Endacea's recent composition of matter patents include allergic rhinitis and chronic obstructive pulmonary disease.

In 2008, Endacea responded to an RFA from NIH/NIAID for “Medical Countermeasures for Radiation-Induced Pulmonary Injury” with an application entitled “A Novel Treatment for Ionizing Radiation Pneumonitis and Fibrosis Targets A₁ ARs” that made the case for the use of L-97-1 to treat victims of a “dirty bomb” attack.  Endacea is currently seeking funding for proof of concept animal studies.  With success, Endacea expects to attract material follow-on funding by the U.S. government for this high priority unmet nuclear defense and medical need.  Endacea expects that a licensee interested in clinical indications, e.g. adjunctive use by radiation oncologists treating patients with lung cancer, would benefit from government funded development of this technology.

In April 2006, Endacea licensed several patents relating to the use of P2X purinoceptor antagonists and A₁ adenosine receptor antagonists to treat ischemia reperfusion injury to Medicure International, Inc., a wholly owned subsidiary of Medicure, Inc. As a result of this license, Endacea received a $500,000 license fee and acquired a royalty interest in Medicure's lead compound, MC-1. Because MC-1 did not meet its principal end point in a pivotal Phase III clinical trial, Endacea does not expect to receive additional revenues from this license agreement.